Get started
Senseonics Holdings, Inc.Senseonics Holdings, Inc.Senseonics Holdings, Inc.

Senseonics Holdings, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

SENS trade ideas

SENS - Bull pennant (again)SENS has been rising on good momentum and right now it appears a second bull pennant is in the works. Good chance of the stock rising to 4.90 (next resistence). If it can surpass and close above a final resistence @ 5.29 eventually, then it will be all-time-high and there is good chance for the stock to trend on a longer term . "The trend is our friend until it bends". Disclaimer: This is just my own analysis and opinion for discussion and is not a trade advice. Kindly do your own due diligence and trade according to your own risk tolerance. Thank you. Feel free to give me your thoughts ! :)
AMEX:SENSLong
by Juliac
6
$SENS broke out of pennant pre marketHello dear padawans of the charts. It looks like SENS broke out of the pennant pre market. You can monitor the price from here for a re-test of the pennant resistance as support or for a drop back within the pennant. If the top of the pennant becomes support we could start rallying again after this brief accumulation within the pennant (the price could also continue moving up without any re-test). RSI looks healthy as well as MACD. I entered a swing trade position here. Safe trades! Show your love: If you get anything out of this TA, please hit the like button so other can find this analysis quicker. Follow for more: If you want the best entry/exits just follow me, you won't regret. Thanks a lot! ***The ideas shared here are my opinion, not financial advise to place trades. Please do your own research before buying/selling stocks***
AMEX:SENS
by Safe_Trades
13
SENSSENS: Many in private have asked me what I thought of GME and if from my ideas something highly explosive like GME could be born in a short time, my answer was the following ... OCGN and SENS ..... Sens why? So FDA approval of their 180-day monitor is forthcoming. It was delayed due to Covid, not a trial failure (the system is already used outside the US) Their new partner, Ascencia, seems more suitable than their previous partner Roche & George Soros is more attached to this pennystock. With a 5 mm cut they bring the sensor into the arm. First of all this is very good so you can't really see the sensor from the outside what all other sensor manufacturers have like DEXCOM. the only thing you have on your arm is a device that detects your sugar level signal. You can take it off and put it back on. The sensor will vibrate when you are too high or low. You just have to replace it every 180 days (another 10 days). Let's get to the core ... DEXCOM's first competitors ($ 400 per share is worth) you know who it is? Yes it is SENS .... So from 2.98 $ I'm there ... over 5.5$ all as GME is relly possibily I hope my idea can make you understand that behind the results, there are researches ... Happy Trading everyone www.paypal.me
AMEX:SENSLong
by mauretto432
7
Expected net revenue increasedFourth quarter 2020 net revenue is expected to be approximately $3.5 million, increased from the prior expectation of approximately $2.5 million Received communication from the FDA explaining the reallocation of agency resources to address Emergency Use Authorization (EUA) applications for products related to the COVID-19 public health emergency is affecting marketing application reviews, including the Eversense 180-day product, which will be delayed by at least 60 days. This is consistent with what Senseonics understands other medical technology companies have reported. Inclusion of Eversense Category III CPT codes in the Centers for Medicare & Medicaid Services (CMS) 2021 Physician Fee Schedule (PFS), establishing global payment for the device cost and procedure fees for healthcare providers across the United States Full year 2021 net revenue is expected to be between $12 and $15 million, based on installed base, acceleration of Ascensia’s commercial activities and other factors Reached agreement with Roche to facilitate transition of distribution to Ascensia, as Roche sales conclude January 31, 2021, including final purchases, transition support activities, and resolution of other matters Highbridge second lien loan extinguished through completed conversion of their second lien debt to common stock, simplifying capital structure "Strong fourth quarter performance was driven by sales in Europe and supported by Ascensia’s initial US sales." We remain confident that the PROMISE study demonstrates that the excellent performance of the current Eversense system is extended for up to 180 days, and that there still is potential for a decision from the agency by the end of the end of the second quarter finance.yahoo.com
AMEX:SENS
by AlenCiken
1